Save up -80% on Imatinib

Note: this is a drug discount program, not an insurance plan.
RX BIN: 015558RX PCN: HTGroup ID: DDN6600Card Holder ID: DDN6600
Pharmacists and Patients support.

2019 Price of Gleevec

$2,789.4630 tablets/100mg
price without discount in nearest pharmacy. Price may vary.

Claim your free Imatinib discount card

We offer free Gleevec coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Imatinib every time. What are you waiting for? Claim your prescription drug card now!

Walgreens pharmacy
Walgreens pharmacy
CVS pharmacy
CVS pharmacy
Walmart pharmacy
Walmart pharmacy
Ride AID pharmacy
Ride AID pharmacy
CVS Target pharmacy
CVS Target pharmacy
Kroger pharmacy
Kroger pharmacy
rx

Get your Prescription

safe

It’s safe and free

pharmacy

Buy drugs in pharmacy

save money

Save money each time

Imatinib volume of distribution

Population mean estimates (95% confidence interval) at day 1 for apparent clearance (CL) and apparent volume of distribution (V) of imatinib were 14 (13–15) l h−1 and 252 (237–267) l, respectively.

RX Prescription
Ask Your therapeut before taking any drugs.

About RX24Drugs

2018 Statistics

discount card

Discount Cards 16,000+

benefit

Clients Benefit 29%

savings

Total savings $4,735,080

What is Imatinib

Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.

Imatinib mechanism of action

Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML). It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib also inhibits the receptor tyrosine kinases for platelet derived growth factor (PDGF) and stem cell factor (SCF) – called c-kit. Imatinib was identified in the late 1990s by Dr Brian J. Druker. Its development is an excellent example of rational drug design. Soon after identification of the bcr-abl target, the search for an inhibitor began. Chemists used a high-throughput screen of chemical libraries to identify the molecule 2-phenylaminopyrimidine. This lead compound was then tested and modified by the introduction of methyl and benzamide groups to give it enhanced binding properties, resulting in imatinib.

Dosage forms of Imatinib

DrugDosageQuantityPrice
Imatinib100mg30 Tablet$62.80
Imatinib100mg90 Tablet$188.75
Imatinib400mg30 Tablet$230.90
Imatinib400mg90 Tablet$694.75

Prescription Generics

false

International Brands

Act Imatinib

Synonyms

4-(4-METHYL-piperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-benzamide alpha-(4-Methyl-1-piperazinyl)-3′-((4-(3-pyridyl)-2-pyrimidinyl)amino)-P-toluidide

Manufacturers

Actavis Pharma Company

CAS number

152459-95-5

UNII

BKJ8M8G5HI

State

solid

Affected organisms

Humans and other mammals

Indication of Imatinib

For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).

Toxicity of Imatinib

The most frequently reported adverse reactions (30%) were edema, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue and abdominal pain.

RX24 Drugs Disclaimer: consult your healthcare provider before buying a Imatinib on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Imatinib now!